Gilead Sciences Inc. (GILD) Short Interest Update
Gilead Sciences Inc. (NASDAQ:GILD) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 13,242,514 shares, a decrease of 8.4% from the September 15th total of 14,451,514 shares. Based on an average daily trading volume, of 10,204,094 shares, the short-interest ratio is currently 1.3 days. Currently, 1.0% of the company’s stock are short sold.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 72.75 on Friday. The stock’s 50 day moving average is $77.93 and its 200 day moving average is $84.45. Gilead Sciences has a 52-week low of $72.21 and a 52-week high of $111.11. The stock has a market cap of $96.01 billion, a price-to-earnings ratio of 6.38 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. The business had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.15 earnings per share. On average, equities analysts expect that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.58%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s payout ratio is 16.56%.
In other Gilead Sciences news, insider John F. Milligan sold 70,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now owns 1,128,963 shares in the company, valued at $87,765,583.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its position in shares of Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock valued at $181,075,000 after buying an additional 8,430 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock valued at $159,794,000 after buying an additional 258,807 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock valued at $1,137,969,000 after buying an additional 161,505 shares during the last quarter. Temasek Holdings Private Ltd increased its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock valued at $1,270,471,000 after buying an additional 1,035,592 shares during the last quarter. Finally, Omega Advisors Inc. purchased a new position in shares of Gilead Sciences during the first quarter valued at about $47,491,000. 77.93% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have weighed in on the company. Jefferies Group upped their target price on Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, October 5th. RBC Capital Markets reiterated a “buy” rating and set a $95.00 price objective (down previously from $105.00) on shares of Gilead Sciences in a report on Monday, October 3rd. Royal Bank Of Canada increased their price objective on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, October 3rd. Leerink Swann reiterated an “outperform” rating and set a $112.00 price objective on shares of Gilead Sciences in a report on Friday, September 30th. Finally, Goldman Sachs Group Inc. reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Tuesday, September 27th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $104.71.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.